Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers


  Free Subscription

Articles published in Gut

Retrieve available abstracts of 40 articles:
HTML format

Single Articles

    November 2023
  1. WANG Y, Li Q, Li C, Wang C, et al
    Chimeric antigen receptors of HBV envelope proteins inhibit hepatitis B surface antigen secretion.
    Gut. 2023 Nov 16:gutjnl-2023-330537. doi: 10.1136/gutjnl-2023-330537.
    PubMed     Abstract available

  2. YU X, Gong Q, Yu D, Chen Y, et al
    Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss.
    Gut. 2023 Nov 15:gutjnl-2023-330577. doi: 10.1136/gutjnl-2023-330577.
    PubMed     Abstract available

    October 2023
  3. TESTONI B, Scholtes C, Plissonnier ML, Paturel A, et al
    Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B.
    Gut. 2023 Oct 25:gutjnl-2023-330644. doi: 10.1136/gutjnl-2023-330644.
    PubMed     Abstract available

  4. CHOI WM, Kim GA, Choi J, Choi GH, et al
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Gut. 2023 Oct 9:gutjnl-2023-330225. doi: 10.1136/gutjnl-2023-330225.
    PubMed     Abstract available

  5. LIU Z, Lin C, Mao X, Guo C, et al
    Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people.
    Gut. 2023 Oct 5:gutjnl-2023-330691. doi: 10.1136/gutjnl-2023-330691.
    PubMed     Abstract available

    September 2023
  6. LE BERT N, Fisicaro P
    Enolase: a metabolic checkpoint behind diverse exhaustion stages of CD8+ T cells in chronic HBV and HCV.
    Gut. 2023 Sep 6:gutjnl-2023-330541. doi: 10.1136/gutjnl-2023-330541.

    August 2023
  7. WINKLER F, Hipp AV, Ramirez C, Martin B, et al
    Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8(+) T cells.
    Gut. 2023 Aug 4:gutjnl-2022-328734. doi: 10.1136/gutjnl-2022-328734.
    PubMed     Abstract available

  8. MENG CY, Sun S, Liang Y, Xu H, et al
    Engineered anti-PDL1 with IFNalpha targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance.
    Gut. 2023;72:1544-1554.
    PubMed     Abstract available

    March 2023
  9. GIRALDEZ-GALLEGO A, Rodriguez-Seguel EDP, Valencia-Martin R, Morillo-Garcia A, et al
    Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial.
    Gut. 2023 Mar 24:gutjnl-2022-328222. doi: 10.1136/gutjnl-2022-328222.
    PubMed     Abstract available

    January 2023
  10. ROSSI M, Vecchi A, Tiezzi C, Barili V, et al
    Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro.
    Gut. 2023 Jan 30:gutjnl-2022-327202. doi: 10.1136/gutjnl-2022-327202.
    PubMed     Abstract available

  11. ALLWEISS L, Testoni B, Yu M, Lucifora J, et al
    Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure.
    Gut. 2023 Jan 27:gutjnl-2022-328380. doi: 10.1136/gutjnl-2022-328380.
    PubMed     Abstract available

  12. TESTONI B, Ploss A
    Cracking the host functional network involved in hepatitis B virus cccDNA biology.
    Gut. 2023 Jan 27:gutjnl-2022-329185. doi: 10.1136/gutjnl-2022-329185.

  13. JANSSEN HLA, Hou J, Asselah T, Chan HLY, et al
    Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
    Gut. 2023 Jan 25:gutjnl-2022-328041. doi: 10.1136/gutjnl-2022-328041.
    PubMed     Abstract available

  14. HENDRIKX T, Lang S, Rajcic D, Wang Y, et al
    Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice.
    Gut. 2023 Jan 23:gutjnl-2022-328265. doi: 10.1136/gutjnl-2022-328265.
    PubMed     Abstract available

  15. EFFENBERGER M, Widjaja AA, Grabherr F, Schaefer B, et al
    Interleukin-11 drives human and mouse alcohol-related liver disease.
    Gut. 2023;72:168-179.
    PubMed     Abstract available

    October 2022
  16. LANG-MELI J, Neumann-Haefelin C
    Prophylactic vaccination against hepatitis D virus superinfection: from fiction to reality?
    Gut. 2022 Oct 19. pii: gutjnl-2022-328381. doi: 10.1136/gutjnl-2022-328381.

    September 2022
  17. VENTURA-COTS M, Argemi J, Jones PD, Lackner C, et al
    Clinical, histological and molecular profiling of different stages of alcohol-related liver disease.
    Gut. 2022;71:1856-1866.
    PubMed     Abstract available

    August 2022
  18. BURM R, Maravelia P, Ahlen G, Ciesek S, et al
    Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.
    Gut. 2022 Aug 17. pii: gutjnl-2022-327216. doi: 10.1136/gutjnl-2022-327216.
    PubMed     Abstract available

  19. ALZUA GP, Pihl AF, Offersgaard A, Duarte Hernandez CR, et al
    Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice.
    Gut. 2022 Aug 2. pii: gutjnl-2021-326323. doi: 10.1136/gutjnl-2021-326323.
    PubMed     Abstract available

  20. LAUER GM
    Omics studies in gastroenterological and hepatological patient populations: current impact and future promise exemplified by a large study of HCV-infected livers.
    Gut. 2022 Aug 1. pii: gutjnl-2022-327761. doi: 10.1136/gutjnl-2022-327761.

    July 2022
  21. WIGGINS BG, Pallett LJ, Li X, Davies SP, et al
    The human liver microenvironment shapes the homing and function of CD4(+) T-cell populations.
    Gut. 2022;71:1399-1411.
    PubMed     Abstract available

    May 2022
  22. MARCHI E, Ramamurthy N, Ansari MA, Harrer CE, et al
    Defining the key intrahepatic gene networks in HCV infection driven by sex.
    Gut. 2022 May 25. pii: gutjnl-2021-326314. doi: 10.1136/gutjnl-2021-326314.
    PubMed     Abstract available

  23. GORGULU E, Gu W, Trebicka J, Mucke VT, et al
    Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic?
    Gut. 2022;71:1036-1038.

    February 2022
  24. ALLWEISS L, Giersch K, Pirosu A, Volz T, et al
    Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo.
    Gut. 2022;71:372-381.
    PubMed     Abstract available

    January 2022
  25. LI J, Liang X, Jiang J, Yang L, et al
    PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF.
    Gut. 2022;71:163-175.
    PubMed     Abstract available

    October 2021
  26. ALIABADI E, Urbanek-Quaing M, Maasoumy B, Bremer B, et al
    Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection.
    Gut. 2021 Oct 26. pii: gutjnl-2021-324646. doi: 10.1136/gutjnl-2021-324646.
    PubMed     Abstract available

  27. HSU YC, Tseng CH, Su TH, Kao JH, et al
    Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities.
    Gut. 2021 Oct 20. pii: gutjnl-2021-326232. doi: 10.1136/gutjnl-2021-326232.

  28. TRIVEDI PJ, Hirschfield GM
    Recent advances in clinical practice: epidemiology of autoimmune liver diseases.
    Gut. 2021;70:1989-2003.
    PubMed     Abstract available

    September 2021
  29. HALL SAL, Vogrin S, Wawryk O, Burns GS, et al
    Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.
    Gut. 2021 Sep 7. pii: gutjnl-2020-323979. doi: 10.1136/gutjnl-2020-323979.
    PubMed     Abstract available

    June 2021
  30. URBAN S, Neumann-Haefelin C, Lampertico P
    Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.
    Gut. 2021 Jun 8. pii: gutjnl-2020-323888. doi: 10.1136/gutjnl-2020-323888.
    PubMed     Abstract available

    May 2021
  31. SUN J, Wu G, Pastor F, Rahman N, et al
    RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
    Gut. 2021 May 21. pii: gutjnl-2020-323126. doi: 10.1136/gutjnl-2020-323126.
    PubMed     Abstract available

  32. JINDAL A, Vyas A, Dubey G
    Ponder of concern and long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil.
    Gut. 2021 May 5. pii: gutjnl-2021-324967. doi: 10.1136/gutjnl-2021-324967.

    April 2021
  33. PHAM LV, Pedersen MS, Fahnoe U, Fernandez-Antunez C, et al
    HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
    Gut. 2021 Apr 8. pii: gutjnl-2020-323585. doi: 10.1136/gutjnl-2020-323585.
    PubMed     Abstract available

    March 2021
  34. HERNAEZ R, Thimme R
    End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma.
    Gut. 2021 Mar 30. pii: gutjnl-2021-324288. doi: 10.1136/gutjnl-2021-324288.

  35. LI J, Li J, Chen S, Yuan Q, et al
    Naturally occurring 5' preS1 deletions markedly enhance replication and infectivity of HBV genotype B and genotype C.
    Gut. 2021;70:575-584.
    PubMed     Abstract available

    February 2021
  36. WIJAYA RS, Read SA, Truong NR, Han S, et al
    HBV vaccination and HBV infection induces HBV-specific natural killer cell memory.
    Gut. 2021;70:357-369.
    PubMed     Abstract available

    December 2020
  37. KIM MA, Kim SU, Sinn DH, Jang JW, et al
    Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
    Gut. 2020;69:2214-2222.
    PubMed     Abstract available

    October 2020
  38. CASTRY M, Cousien A, Supervie V, Velter A, et al
    Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach.
    Gut. 2020 Oct 27. pii: gutjnl-2020-321744. doi: 10.1136/gutjnl-2020-321744.
    PubMed     Abstract available

    September 2020
  39. ESPARZA-BAQUER A, Labiano I, Sharif O, Agirre-Lizaso A, et al
    TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Gut. 2020 Sep 9. pii: gutjnl-2019-319227. doi: 10.1136/gutjnl-2019-319227.
    PubMed     Abstract available

    March 2020
  40. JUHLING F, Hamdane N, Crouchet E, Li S, et al
    Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
    Gut. 2020 Mar 26. pii: gutjnl-2019-318918. doi: 10.1136/gutjnl-2019-318918.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.